Cirque de Navacelles Grand Site France, Saint-Guilhem-le-Désert UNESCO 804, Pont du Diable Clamouse, Lac Salagou ruffe rouge, ...

Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial, furthering its ambitions to establish divarasib as a new standard of care ...

Already approved for lupus nephritis, Roche's Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder after clearing a phase 3 trial. The results of the ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...

Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist’s market share with its own next-gen platform. Roche’s Axelios 1 delivers ...

Seventy-two years after the Roche family opened a meat market that grew into a Massachusetts supermarket chain, the family is selling a controlling interest in the company to a longtime supplier in ...

Vide-greniers, feux d’artifice, concerts, marchés de producteurs… voici une quarantaine d’idées de sorties en ce long ...

Fête de la truffade, à la Vidalie, vendredi à partir de 19 heures ; samedi et dimanche, toute la journée : course de vélo, ...

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as ...

La chanteuse québécoise, très en voix, chante la gratitude et l’amour à travers cette mélodie efficace et moderne dont le refrain nous reste en tête. « Bonjour, pardon, merci, il manque un vers à ce ...

Trois mois après Dansons, sortie en avril dernier, Céline Dion poursuit son grand retour avec Bonjour, Pardon, Merci, une nouvelle chanson originale lancée aujourd’hui — la deuxième d’une année qui ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.